[REVISION HISTORY]

Telix Pharmaceuticals diagnostic drug developments

Updated 1 time since CLSTR started tracking revisions of this situation.

What changed

2026-09-30 01:47 UTC → 2026-10-07 23:32 UTC · added ~~removed~~

Telix Pharmaceuticals has achieved regulatory milestones for its diagnostic imaging products in the United States. The FDA approved Pixclara (floretyrosine F 18), a radioactive drug for imaging gliomas in both adult and pediatric patients. This approval provides a tool to help clinicians differentiate between recurrent or progressive glioma and changes from previous treatments. Following this, the FDA granted Fast Track designation to Telix’s BiPASS program. This program combines gallium-68 PSMA-PET imaging with MRI to facilitate earlier and less invasive prostate cancer diagnosis, aiming to reduce the frequency of unnecessary biopsies. Following the Fast Track designation, UBS upgraded its share price target for Telix Pharmaceuticals. Analysts noted that a successful BiPASS study could “nearly double the total addressable market for Telix’s PSMA compounds.” The broker suggested that the market may be underestimating the commercial potential and the probability of success for this diagnostic tool, which addresses a significant unmet medical need in prostate cancer care.

Versions

Only revisions since CLSTR began indexing content versions appear here. Select a version to see what changed compared to the one before it.